You are here
June 12, 2018
Test vaccine active against many HIV strains
At a Glance
- An HIV vaccine tested in animals prompted the immune system to form antibodies that neutralize dozens of HIV strains.
- A small study of the test vaccine in people is expected to begin in late 2019.
Infection with HIV, the virus that causes AIDS, makes a person vulnerable to many other infections and diseases. So far, researchers have not been able to create an effective HIV vaccine, in part because there are many different strains of the virus.
Some people with HIV infection make antibodies that can neutralize multiple HIV strains. Scientists have studied these antibodies to find clues about how they bind to the virus and neutralize it. Over the past several years, HIV researchers have identified many broadly neutralizing antibodies that can protect human cells in the lab. Scientists examine the sites, or epitopes, on HIV where each known broadly neutralizing antibody binds. They then try to figure out how to make a vaccine based on those epitopes to prompt the immune system to form antibodies. The hope is that these vaccine-induced broadly neutralizing antibodies will protect people from HIV infection.
In 2016, scientists at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) identified an epitope that’s thought to be similar across most HIV strains. Called the HIV fusion peptide, it’s part of the spike on the HIV surface that helps the virus enter a person’s cells. A research team led by Drs. Peter D. Kwong and John R. Mascola of NIAID’s Vaccine Research Center set out to develop an HIV vaccine that targets the HIV fusion peptide. The research was published in Nature Medicine on June 4, 2018.
The research team engineered proteins called immunogens that were designed to activate an immune response against the HIV fusion peptide based on its known structure. The team tested which immunogens most effectively elicited HIV-neutralizing antibodies to the fusion peptide. The best immunogen consisted of eight amino acids of the fusion peptide bonded to a carrier protein often used to boost the immune response.
To improve their results, the team paired this immunogen with a replica of the HIV spike. They tested several vaccine regimens in mice and analyzed the antibodies generated. Antibodies prompted by the vaccines attached to the HIV fusion peptide and neutralized up to 31% of viruses in a panel of 208 HIV strains from around the world.
The researchers used the lessons learned from these experiments and tested modified vaccine regimens in guinea pigs and monkeys. These animals also formed broadly neutralizing antibodies that were active against dozens of HIV strains.
These findings in mice, guinea pigs, and monkeys show that the vaccine regimen can work in several species. The scientists are now working to improve the regimen and test it further in monkeys. A small study of the new vaccine in people is anticipated to begin in late 2019.
“NIH scientists have used their detailed knowledge of the structure of HIV to find an unusual site of vulnerability on the virus and design a novel and potentially powerful vaccine,” says NIAID Director Dr. Anthony S. Fauci. “This elegant study is a potentially important step forward in the ongoing quest to develop a safe and effective HIV vaccine.”
- Engineered Antibody Protects Monkeys From HIV-Like Virus
- Dual Antibody Treatment Suppresses HIV-Like Virus in Monkeys
- HIV Vaccine Progress in Animal Studies
- HIV Immunotherapy Promising in First Human Study
- The Structure and Dynamics of HIV Surface Spikes
- Making Antibodies That Neutralize HIV
- Antibodies Protect Human Cells From Most HIV Strains
- Insights Into How HIV Evades Immune System
References: Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M, Chen X, Choi CW, Dandey VP, Doria-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD. Nat Med. 2018 Jun 4. doi: 10.1038/s41591-018-0042-6. [Epub ahead of print]. PMID: 29867235.
Funding: NIH’s National Institute of Allergy and Infectious Diseases (NIAID), National Institute of General Medical Sciences (NIGMS), and Office of the Director; Simons Foundation; Empire State Development's Division of Science, Technology, and Innovation (NYSTAR); and Agouron Institute.